30 April 2019
Animalcare Group plc
("Animalcare", the "Company" or the "Group") Full Year Results for the 12 months ended 31 December 2018
Animalcare Group plc (AIM: ANCR), the European Animal Health business, announces its full year results for the year ended 31 December 2018.
Financial Highlights
• Reported revenue growth of 16.3% to £72.5m (2017: £62.3m) o Up 2.7% on a proforma basis
• Underlying* EBITDA increased by 21.7% to £11.8m (2017: £9.7m) o Up 2.8% on a proforma basis
• Statutory loss before tax, which incorporates non-underlying items, decreased to £0.4m (2017: £0.4m profit) with reported basic loss per share decreased to 1.7p (2017: 0.2p earnings per share)
• Improved underlying* cash conversion to 79.9% (2017: 65.9%) with net debt reduced by £2.3m to £23.6m
• Proposed final dividend of 2.4 pence per share giving a total dividend of 4.4 pence per share for 2018
Operational Highlights (including post-period)
• Jenny Winter, formerly of AstraZeneca, appointed Chief Executive Officer in October 2018
• Leadership team strengthened by appointment of Group Functional leaders in Supply Chain, Commercial, New Product Opportunities (CSO) and Technical / Regulatory functions and HR. In addition, we have appointed new country managers in Spain, the UK and Belgium
• Portfolio prioritisation performed including the sale of the non-core Wholesale business in Q3 2018, in line with focus on the higher-margin veterinary pharmaceuticals business
• Ten new products launched in 2018 with an additional six submissions made for products that are scheduled for launch in 2019 or early 2020
• Strategy was focussed to reflect the new combined Animalcare group and was approved by the Board post period.
It builds on the experience and success of the legacy companies and reflects the rapidly growing and changing marketplace. The Board believe the five strategic priorities below will drive the future success of Animalcare and will contribute to both the short and long-term sustainable growth.
o Build strong financial basis through revenue growth, cash conversion, EPS growth and EBITDA margin growth
o Grow the business through a focussed portfolio of existing products and build a robust future pipeline in five key therapy areas in the companion animal and equine markets
o Build on existing customer relationships with vets and other stakeholders to deliver trusted products and
services
o Business development focus with partners to in license and acquire innovative products
o Organisation for success, building leadership strength and attract, retain and develop talent for the future
*underlying measures are before the effect of non-underlying items which excludes fair value adjustments on acquired inventory, amortisation of acquired intangibles and acquisition and integration costs. A reconciliation to statutory measures is provided in the Chief Financial Officer’s Review.
Jan Boone, Chairman of Animalcare Group plc, commenting on the results said: "Animalcare made good progress in 2018 as we focus on creating a competitive platform for future growth in the global animal health sector. We continue to improve the underlying profitability of the Group, and the disposal of our Wholesale Division was in line with our strategy to focus on the higher-margin veterinary pharmaceuticals business, a key growth driver. In order to maximise our potential as a significant player in the European and international animal health sector, we appointed Jenny Winter as CEO in October 2018 to maximise the potential of the business. With Jenny’s leadership and expertise, I look forward to delivering our financial goals and strategic objectives over the coming years.”
Jenny Winter, CEO of Animalcare Group plc, said: "Since joining Animalcare in October last year, I have been impressed by the competitive strengths of the business and the size of the growth opportunity. I have conducted a detailed review of all areas of the business and set out a strategy to enable us to build upon our capabilities. Our goal is to deliver sustainable and profitable growth and to achieve this, we will focus on meeting the needs of vets in therapeutic areas where we have existing strengths and can further add value. Improving cash generation is a key focus for the business and we will continue to drive improvements in supply chain efficiency and closely monitor our cost base, whilst selectively investing in future innovation.
Achieving this will build an effective and focused organisation that is fit for the future and deliver growth over the next three to five years. ”
Analyst briefing today
Jenny Winter, Chief Executive Officer, and Chris Brewster, Chief Financial Officer, will host a meeting and conference call for analysts to provide an update the Company, followed by a Q&A session, at 09:00am BST today at the offices of Panmure Gordon & Co, One New Change, London, EC4M 9AF.
Dial-in details:
International and UK dial-in:
+44 (0) 2071 928000 Belgium dial-in:
080048740
Conference ID:
5769312
Presentation slides will be made available on Animalcare’s website, www.animalcaregroup.co.uk, prior to the conference call.
For further information, please contact:
Animalcare Group plc Tel: 01904 487 687
Jenny Winter, Chief Executive Officer Chris Brewster, Chief Financial Officer
Panmure Gordon (Nominated Adviser & Broker) Tel: 020 7886 2500 Corporate Finance
Freddy Crossley / Emma Earl Corporate Broking
James Stearns
Consilium Strategic Communications
Tel: 020 3709 5709 Amber Fennell/Jonathan Birt/Angela Gray
/Olivia Manser
Animalcare@consilium-comms.com
About Animalcare (www.Animalcaregroup.co.uk)
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
CHAIRMAN’S STATEMENT
Animalcare continued to make steady progress in 2018 as we focus on creating a competitive platform for future growth in the international animal health sector. Group revenues from continuing operations were up 16.3% to £72.5m from £62.3m with underlying EBITDA increasing by 21.7% to £11.8m (2017: £9.7m). On a proforma basis, which is used by the Board for comparison of financial performance, as set out in the unaudited income statement in the Chief Financial Officer’s Review, revenue and underlying EBITDA growth versus 2017 was 2.7% and 2.8% respectively. After underlying adjustments totalling
£9.4m, the loss before tax for the year on a reported basis was £0.4m (2017: £0.4m profit).
Sales growth was affected towards the end of the year by supply challenges related to third-party manufacturers, some of which impacted the wider market. We also experienced some delays to new product launches and lower demand in the large animal portfolio, particularly for antibiotics which was reflective of an overall market decline in demand.
Strategically, we decided to dispose of the Wholesale Division in order to focus resources on the higher-margin veterinary pharmaceuticals business. We also continued to focus on integration, supply chain efficiency and optimising portfolios and product launches across our expanded network.
The Board is confident of the long-term prospects of the animal health market and is actively preparing the business to make the most of the opportunities. Our key competitive advantages include a significant presence across Europe, with products sold in 32 markets directly and through partners. We also benefit from specialisation in key therapeutic areas for the companion animal and equine markets and believe we can capitalise on a growing reputation as a chosen partner for non-European companies and researchers wanting to commercialise innovative products in Europe.
In order to maximise the potential of the business, the Board appointed Jenny Winter as CEO in October 2018. Jenny has an excellent track record in the pharmaceutical industry, most recently with AstraZeneca, with particular expertise in supply chain effectiveness, which we believe is fundamental to improving our overall performance. We are grateful to Chris Cardon for his contribution as CEO and for taking on the role of Chief Strategy Officer.
Jenny has initiated a full review and identified a clear path for Animalcare as a business focused around core therapy areas and higher margin products with the vet as our primary customer. We are also setting out financial goals, including growing faster than the markets in which we operate and improving cash generation to enable us to invest in future growth and innovation.
Further details of the new strategy are set out in the Chief Executive Officer’s Review and are linked to our Key Performance Indicators.
I would like to thank our employees for their support and dedication during 2018. We look forward to 2019 and beyond with confidence. We believe Animalcare is excellently placed to leverage its geographic, structural and therapeutic strengths, and has the opportunity to become a significant and recognised brand across Europe, with global potential for innovative products through best-in-class partnerships.
We look forward to keeping you updated on our progress during the year.
Jan Boone
Non-Executive Chairman
CHIEF EXECUTIVE OFFICER’S REVIEW
Since joining Animalcare in October 2018, I have been impressed by the competitive strengths of the business and the quality of the growth opportunity. Since joining and following the disposal of our wholesale business in September 2018, a thorough review has been undertaken. Following this review and detailed discussions with the Board, I have set out a strategy to enable us to build on the existing portfolio, experience and capabilities to become an important player in the European animal health market and beyond. I have also reviewed our pipeline and established the principles we will use to build a sustainable future.
The strategy is built around five pillars:
• Strong finances
• Growth portfolio
• Customer relationships
• Focused business development
• The organisation for success
In the seven European markets where we have commercial operations we market and sell our own products. We also market and sell products from other companies through our established sales teams. In countries where we do not have sales teams, we work with our network partners to commercialise our own products. With this footprint we are active in 32 countries in Europe and a further 16 in the rest of the world.
We employ over 110 fully trained sales representative and technical experts who are working closely with our customers including dedicated Key Account Managers who work with our larger Corporate Partners
We have a broad portfolio of licensed drugs, vaccines and care products including nutraceuticals in the companion animal, equine and production animal segments of the market. In the UK we are also one of the leading providers of pet microchips and have a successful pet reunification service.
2018 Operational performance:
Financials
On a proforma basis, sales in 2018 increased by 2.7% to £72.5m versus the prior year and were in line with the market growth for the countries and segments in which we operate. This increase is driven by organic growth in companion animals (+6.0%) offset by a decline in production animal sales of 3.6%.
Growth in Companion Animals was driven by the launch of new products including Cosequin (Spain) and the annualised impact of products launched in 2017. Equine sales were flat and the decline in sales in production animals is driven by the reduction in the use of antibiotics and our antibiotics sales versus 2017 declined at 15%. Belgium and Italy saw the largest decline.
Our top three selling products in 2018 were Dinalgen Injection for the treatment of pain, Conofite, an antifungal treatment and Orozyme, an established oro-dental product and accounted for 12% of sales.
The top 20 products accounted for 47% of our total sales. Filavac (+38%), Aqupharm fluids (+27%) and Cosequin (joint supplement) (+230%) were the most significant growth drivers in the portfolio. Our microchip business in the UK continued to perform well with growth of 31%. Whilst overall sales in farm animal declined, Dinalgen Injection performed strongly with revenue up 31%.
Our operating overheads increased by +0.7% with a mix of increases in employee costs and decreases in other operational expenses.
Underlying EBITDA increased by 2.8% driven by growth in Germany and the UK, offset by a decline in Belgium and Spain.
Overall growth was impacted by some out of stocks due to supply chain challenges, some delays in approvals for new products and the pace of the decline in antibiotic prescribing.
New product launches and regulatory filings.
We have been building our product portfolio and technical efficiencies in 2018. We have made 17 submissions for products that are either new to our portfolio, or new in a specific country both within Europe and Globally. We have made over 50 submissions including extensions to the life cycle of existing products that will increase efficiency and decrease costs.
We launched ten new products in 2018 and will see the full year impact of these launches in 2019.
In 2018 we completed a strategic review of our development pipeline and re focused our activities to drive growth in the next five years.
We have accelerated the development programme for our novel pain treatment by four months and we terminated the development of two products, either due to commercial or technical reasons.
Six projects were submitted to the regulatory authorities in 2018 including extensions to our “Care” range across multiple countries that will strengthen our portfolio in the key therapeutic areas. Launches are planned for these products
throughout 2019 and into early 2020.
People
We have continued the work that was done in 2017 to strengthen our Leadership Team and have established a core team to drive simplicity and avoid duplication. We have appointed Martin Gore as our Group Head of Commercial, to drive excellence within our Sales and Marketing teams. Stephen Pearson has been appointed Group Head of Supply Chain and will be focussed on improving customer service and on time in full delivery to our customers as well as managing inventory.
Karolyn Tapper continues to lead our Technical team and Christiaan Cardon has taken the role of Chief Strategy Officer with responsibility for identifying new opportunities for the Group.
The newly created Leadership Team consists of the Group functions and Country Managers to ensure that we remain close to our customers through the leaders in each country. Post year end, we have further strengthened our Country Manager team with the appointment of Sara Maddens to lead the team in Benelux.
Having the right people in place is critical to our long-term success. I am determined that Animalcare will develop a positive and unified culture, with a rewards system and career development path to attract and retain the best talent in our
industry. We plan to introduce a Long-Term Incentive Plan in May 2019 to reward senior employees for sustained performance.
Integration
Animalcare has not yet seen the benefit of the combined organisation in the financial returns however great progress has been made on the 5 key areas outlined in plan in the past six months. Our highest priorities are:
1. Drive maximum value from the combined portfolio.
2. Establish a robust supply chain.
3. Align our pipeline to the growth strategy
4. Align our people strategy including our reward system.
5. Drive commercial excellence
We have established a new Leadership Team and organisational structure to facilitate the implementation of the
integration plan and to drive performance including through simplification, focus and cross functional working. Clear targets are in place to track our progress.
Our growth strategy
To deliver sustainable and profitable growth we will focus on therapeutic areas where we have existing capabilities and with the greatest growth potential, through higher margin innovation, expansion of our geographic reach and careful control of our costs. By growing faster than the markets where we operate, controlling OPEX and improving operating cash
conversion, we can focus resources where they will bring the best returns while continuing to reward shareholders.
Our future Pipeline
Our pipeline will focus on five therapeutic areas in the companion animal and equine markets where we are already strong and have the potential to add value through innovation. These are pain management, dermatology, dental, disease
prevention and surgery. Animalcare also owns identichip, the UK’s leading pet microchipping business and database, with significant scope for growth in the UK and internationally.
We will continue to support our production animal business through targeted products with specific customer groups.
Our customers
We will focus on vets and veterinary groups as our main customers, benefiting from our existing expertise and strong relationships. We want to become the chosen partner in Europe for innovative animal health products for companies around the world. We will seek to improve the quality and profitability of our portfolio by in-licensing and acquiring late- and commercial-stage products, and accelerating our own R&D through targeted investment.
Our footprint
We have established networks in 25 countries in Europe and another 16 globally. We will continue to develop these
networks to maximise the sales of our products and where it makes sense to establish a presence we will do so – either as a stand-alone business or in partnership.
Summary and outlook
We are building an effective and focussed organisation that is fit for the future and we have a clear strategy to grow over the next 3 to 5 years. One of the critical things for our organisation is to track progress and we have established goals, objectives and measures so we can ensure we achieve our financial targets. We have established clear milestones and will report against those. To deliver on the expectations we set,we will focus on generating cash for investing, for rewarding our shareholders and for paying our debt. Success will be driven by the 5 pillars of our strategy - Strong finances, a portfolio for growth, our customer relationships, our business development and most importantly – our organisation of highly engaged and talented people.
I look forward to sharing more details over the coming weeks, months and years as we implement our strategy for success.
Jenny Winter
Chief Executive Officer
CHIEF FINANCIAL OFFICER’S REVIEW Introduction and presentation of results
On 13th July 2017, Animalcare Group plc completed the reverse acquisition of Ecuphar NV. 2018 therefore reflects the first full year of trading as a combined Group. On a statutory basis, and in accordance with IFRS3, the results for the comparative year ended 31st December 2017 represent twelve months of Ecuphar NV and approximately five and a half months of Animalcare Group plc as previously constituted.
In addition, following the divestment of our Wholesale business on 4th September 2018, both the 2018 and 2017 financial information have been presented to show the Pharmaceuticals segment as continuing operations separately from the Wholesale segment, which has been classified as discontinued.
Accordingly, to help Shareholders to assess the Group, an unaudited Proforma Consolidated Income Statement has been provided, which reflects twelve months of trading from the continuing Pharmaceuticals segment for both entities for 2018 and 2017. The Board believes that this statement provides the most appropriate basis for comparison of current and future operating performance. On this basis, the Group has delivered proforma revenue growth of 2.7% to £72.5m (2017: £70.6m) and proforma underlying EBITDA growth of 2.8% to £11.8m (2017: £11.5m). On a statutory basis, including non-underlying items, the Group delivered a loss after tax of £0.8m (2017: £0.2m profit).
Underlying and Statutory Results
To provide comparability across reporting periods, the Group presents its results on both an underlying and statutory (IFRS) basis. The Directors believe that presenting our financial results on an underlying basis, which exclude non – underlying items, provides a clearer understanding of business performance. IFRS results include these items to provide the statutory results. All figures are reported at actual exchange rates (AER) unless otherwise stated. Commentary will include references to constant exchange rates (CER) to identify the impact of foreign exchange movements. A reconciliation between
underlying and statutory results is provided at the end of this financial review.
Financial Review
Pro forma Consolidated Income Statement (unaudited)
Compared to the statutory results for 2018, the unaudited Pro forma Consolidated Income Statement set out below represents the continuing pharmaceuticals segment for both 2018 and 2017, with the 2017 comparatives including an additional 28 weeks of Animalcare Group plc’s results prior to the reverse acquisition. This has the impact of increasing 2017 revenue and underlying EBITDA by £8.3m and £1.8m respectively as set out in the table below
:
Revenue
On a proforma basis, the Group delivered revenue growth of 2.7% to £72.5m (2017: £70.6m), split by product category as shown in the table below:
Companion Animals revenue continues to be the largest proportion of the Group’s business, representing 61.4% of total sales, up from 59.4%. As our existing portfolio continues to mature and be impacted by pricing pressure and changes in the competitor landscape, new products remain the main driver for the overall revenue growth of 6.0% to £44.5m (2017:
£41.9m). We launched seven new products during the year including the nutritional supplement Cosequin in Spain, which contributed £2.4m sales in total. This was supplemented by £0.8m annualised growth of products launched in 2017 that were sourced from our partners, principally in Germany. Overall growth was impacted by supply challenges towards the year end relating to certain third-party manufacturers.
Production Animals revenue contracted by 3.6% versus prior year period largely driven by lower demand for antibiotics offset in part by higher export sales of in particular Dinalgen (anti-inflammatory). Equine and other sales were broadly flat at £5.2m.
Underlying proforma continuing EBITDA increased by 2.8% to £11.8m with corresponding margin consistent with prior year at 16.3%. Gross margins at 51.5% modestly declined compared to prior year (2017: 52.1%) primarily reflecting lower margin sales mix in Companion Animals and the competitive environment. SG&A costs as a percentage of revenue reduced in the year from 35.9% to 35.2% as the business has continued to focus on costs efficiencies whilst investing in our people to support the integration and future growth.
Underlying proforma continuing basic EPS increased by 8.3% for the year to 11.7p, based on a weighted average number of shares of 60.0m applied to both 2018 and 2017. The effective tax rate was 22.3% (2017: 23.0%) primarily reflecting
increased research and developments tax credits and partial utilisation of tax losses.
Underlying and Statutory Results
Unaudited Unaudited
Continuing Operations 2018
£’000
Continuing Operations –Post- acquisition
2017
£’000
Animalcare pre- acquisition
2017
£’000
Total proforma Continuing Operations 2017
£’000
Revenue 72,470 62,291 8,267 70,558
Gross Profit 37,339 32,325 4,464 36,789
Operating expenses (37,122) (31,309) (5,753) (37,062)
Operating profit/(loss) 217 1,016 (1,289) (273)
Depreciation, amortisation & impairment 9,588 6,480 199 6,679
Non-underlying items 1,993 2,202 2,867 5,069
Underlying EBITDA 11,798 9,698 1,777 11,475
Net financial expenses (574) (639) (1) (640)
Profit/(loss) before tax (357) 377 (1,290) (913)
Taxation 135 (292) (82) (374)
Net (loss)/profit (222) 85 (1,372) (1,287)
Underlying net profit 7,016 5,175 1,309 6,484
Underlying basic EPS (p) 11.7p – – 10.8p
Unaudited Unaudited 2018
£’000
2017
£’000
% Change at AER
%
Companion Animals 44,465 41,937 6.0%
Production Animals 22,824 23,680 (3.6%)
Equine and other 5,181 4,941 1.4%
Total 72,470 70,558 2.7%
As a result of the reverse acquisition of Ecuphar NV, both the underlying and statutory basis for reporting results for the year ended 31st December 2017 include approximately five and a half months of Animalcare Group plc as previously constituted. The 2018 results are those noted in the unaudited Proforma Consolidated Income Statement above.
Overview of Underlying financial results – Continuing Operations
We delivered revenue of £72.5m and underlying EBITDA of £11.8m, representing growth of 16.3% and 21.7% respectively compared to the previous year. This was achieved through a combination of modest underlying growth as noted in the proforma results review together with a full year trading impact of the acquired Animalcare operations.
Underlying EBITDA margin improved to 16.3% largely reflecting the higher margin Animalcare business together with overall focus on costs to improve operating leverage. This focus includes a restructuring of our UK commercial team to put more emphasis on supporting larger corporate customers as well as continuing to provide strong service levels to independent practices. We expect this trend to continue and will closely monitor and adapt the Group’s operations accordingly.
Basic underlying EPS decreased to 11.7 pence reflecting the 35.6% increase in underlying profit after tax to £7.0m offset by the significant increase in the weighted average number of shares resulting from the full year impact of the reverse
acquisition (see note 8).
Overview of reported financial results
Including the loss from the discontinued operations and non-underlying items, the Group reported a loss after tax of £1.0m (2017: £0.2m profit).
A reconciliation of underlying results to reported results for the year to 31st December 2018 is shown in the table below:
The sale of our wholesale division was completed on 4th September 2018 with financial effect from 1st July 2018. The loss from discontinued operations was £0.8m which primarily represents the loss on disposal. Additional details are shown in note 4. Of the total £3.0m consideration, £2.4m has been received with a further £0.4m payable to the Group on 30th June 2019 in relation to the remaining intercompany balance owed. The balance of approximately £0.2m is subject to achieving specific revenue targets between 1st July 2019 and 30th June 2020 and payable in July 2020.
2018
£’000
2017
£’000
% Change at AER
%
Revenue 72,470 62,291 16.3%
Gross Profit 37,339 32,325 15.5%
Gross Margin % 51.5% 51.9% (0.4%)
Underlying Operating Profit 9,604 7,560 27.8%
Underlying EBITDA 11,798 9,698 21.7%
Underlying EBITDA margin % 16.34% 15.6% 0.8%
Basic Underlying EPS (p) 11.7p 12.3p (4.9%)
2018 Underlying results
£’000
Discontinue d operations
£’000
Amortisation and impairment of intangibles
£’000
Acquisition, restructuring, integration and other costs
£’000
2018 Reported results
£’000
2017 Reported results (restated)
£’000
Revenue 72,470 – – – 72,470 62,291
Gross Profit 37,339 – – – 37,339 31,924
Selling, general & administrative expenses (24,312) – (4,789) – (29,101) (26,396)
Research & development expenses (3,466) – (1,296) – (4,762) (2,799)
Net other operating income (expenses) 43 – (1,309) (1,993) (3,259) (1,713)
Operating Profit 9,604 – (7,394) (1,993) 217 1,016
Net finance expenses (574) – – – (574) (639)
Profit/(loss) before tax 9,032 – (7,394) (1,993) (357) 377
Taxation (2,016) – 1,822 329 135 (292)
Profit/(loss) after tax 7,016 – (5,573) (1,664) (222) 85
Loss/(profit) from discontinued operations – (776) – – (776) 99
Profit/(loss) for the year 7,016 (776) (5,573) (1,664) (998) 184
Basic EPS (p) 11.7p (1.7p) 0.2p
The amortisation and impairment of intangibles charge of £7.4m (pre-tax) principally comprises £4.6m charge arising on the acquired intangibles relating to the reverse acquisition and £2.5m charge in respect of previous acquisitions made by Ecuphar NV, namely Esteve SA which was acquired on 30th April 2015.
The remaining statutory items totalling £2.0m largely relate to restructuring and integration costs as detailed in note 5.
Restructuring costs of £1.2m principally relate to executive changes, senior management restructuring and the UK commercial team reorganisation as noted earlier.
The reported basic loss per share, which incorporates non-underlying items, decreased to 1.7 pence (2017: 0.2 pence earnings per share).
Dividends
The Board is proposing a final dividend of 2.4 pence per share, adding to the interim dividend of 2.0 pence per share paid in November 2018, giving a total dividend of 4.4 pence per share for the year ended 31st December 2018, the first full
financial year as a combined Group. The Board continues to monitor the dividend policy, recognising the need for a balance between investment to support future growth and dividend flow to deliver overall value to our shareholders.
Cash flow, net debt and borrowing facilities
The Group is committed to improving cash generation, important to generate the funds we need to invest for growth and to maintain dividend payments. We will monitor progress using cash conversion as a percentage of underlying EBITDA as set out in the table below:
The Group’s underlying cash conversion significantly improved during the year to 79.9%, with net cash flow generated by our operations increasing to £7.4m (2017: £2.4m). Working capital increased by £0.9m, largely relating to further increased stocks. Our Group Head of Supply Chain has a clear target to reduce inventory levels over the next two years. Cash taxes of
£2.2m were significantly higher than 2017 largely due to settlement of prior year taxes in Belgium and higher cash tax in Spain.
Net capital expenditure of £4.8m largely comprises investment in our product development pipeline of £4.2m from which six new products are expected to be launched during 2019 and into early 2020. The balance of expenditure largely relates to investment in our IT infrastructure which has made strong progress. This includes a new CRM system in Italy and SAP in the UK which went live on 1st January 2019. Both represent important steps in delivering our objective of common platforms across the Group which will help to drive integration and improve efficiencies.
The net borrowing position at the end of the year was £23.6m, representing net debt to underlying EBITDA leverage of 2.0 times (maximum bank covenant ratio is 3.5 times). At 31st December 2018, total facilities were £46.4m, of which £29.8m, net of cash balances, was utilised, leaving headroom of £16.6m. These bank facilities, together with the Group’s operational cash flow, indicate that the Group has sufficient facilities available to fund its operations and allow for future investment.
Brexit
Whilst the outcome of the Brexit negotiations remain unclear our contingency preparations are on track to maintain commercial supply. We expect to incur one-off costs of circa £0.3m in relation to transfer of product registrations during 2019.
2018
£’000
2017
£’000
Underlying EBITDA 11,798 9,698
Net cash flow from operations 7,430 2,425
Non-underlying items 1,993 3,968
Underlying net cash flow from operations 9,423 6,393
Cash conversion % 79.9% 65.9%
£’000
Net debt at 1st January 2018 (25,908)
Net cash generated from operations 7,430
Net capital expenditure (4,781)
Proceeds from divestment of wholesale operations 2,403
Net finance expenses (626)
Dividends paid (2,401)
Receipts from issue of share capital 170
Other cash movements 474
Foreign exchange on cash and borrowings (349)
Net debt at 31st December 2018 (23,588)
Summary and outlook
The Group delivered continued revenue growth in the year and translation through to both underlying profit and cash conversion is beginning to improve. We remain focused on our medium to long-term objective of delivering sustainable profit growth and improved cash generation, with cash flow expected to be supported by lower inventories.
Strategically and operationally it continues to be a time of change for the Group with the pace of integration of our
businesses accelerating given the greater focus by our Leadership Team. During 2019, the drive for improved efficiency and integration across the business will continue including the integration of our Product Development and Regulatory teams.
We will also focus on portfolio optimisation, improving service and driving efficiencies in our supply chain, all of which will require investment.
Whilst our performance was not as strong as originally expected, we have made steady progress across the business over the last 12 months and delivered growth at a time of much change within our business and the market. We will continue to seek opportunities to grow our business and I believe we are well placed to deliver medium to long-term shareholder value.
Chris Brewster Chief Financial Officer
CONSOLIDATED INCOME STATEMENT YEAR ENDED 31ST DECEMBER 2018
For the year ended 31 December
£’000 Notes
Underlying 2018
Non- Underlying
(note 4) 2018
Total 2018
Underlying 2017 (Restated)
Non- Underlying
(note 4) (Restated)
2017 (Restated)
Total 2017 (Restated)
Revenue 5 72,470 − 72,470 62,291 − 62,291
Cost of sales (35,131) − (35,131) (29,966) (401) (30,367)
Gross profit 37,339 − 37,339 32,325 (401) 31,924
Research and development
expenses (3,466) (1,296) (4,762) (2,048) (751) (2,799)
Selling and marketing expenses (12,435) − (12,435) (12,592) − (12,592)
General and administrative
expenses (11,877) (4,789) (16,666) (10,214) (3,591) (13,805)
Net other operating income /
(expenses) 43 (3,302) 3,259) 89 (1,801) (1,713)
Operating profit/(loss) 9,604 (9,387) 217 7,560 (6,544) 1,016
Financial expenses 6 (840) − (840) (735) − (735)
Financial income 7 266 − 266 96 − 96
Profit/(loss) before tax 9,032 (9,387) (357) 6,922 (6,544) 377
Income tax 8 (2,016) 2,151 135 (1,746) 1,454 (292)
Net profit from continuing
operations 7,016 (7,236) (222) 5,176 (5,090) 85
Net profit/(loss) from
discontinuing operations 3 40 (816) (776) 109 (10) 99
Net profit/(loss) 7,056 (8,052) (998) 5,285 (5,100) 184
Net profit/(loss) attributable to:
The owners of the parent 7,058 (8,052) (996) 5,285 (5,100) 184
Non-controlling interest (2) − (2) − − −
Earnings per share for profit/(loss) from continuing operations attributable to the ordinary equity holders of the company:
Basic earnings per share 9 11.7p (0.4p) 12.3p 0.2p
Diluted earnings per share 9 11.7p (0.4p) 12.3p 0.2p
In order to aid understanding of underlying business performance, the Directors have presented underlying results before the effect of exceptional and other items. These exceptional and other items are analysed in detail in note 4 to this financial information. The accompanying notes form an integral part of these consolidated financial information.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME YEAR ENDED 31ST DECEMBER 2018
* May be reclassified subsequently to profit & loss
CONSOLIDATED STATEMENT OF FINANCIAL POSITION YEAR ENDED 31ST DECEMBER 2018
Earnings per share for profit/(loss) attributable to the ordinary equity holders of the company:
Basic earnings per share 9 11.8p (1.7p) 12.6p 0.4p
Diluted earnings per share 9 11.8p (1.7p) 12.5p 0.4p
£’000 2018 2017
Net (loss)/profit for the year (998) 184
Other comprehensive income
Cumulative translation differences* 165 664
Other comprehensive income, net of tax 165 664
Total comprehensive (expense)/income for the year, net of tax (833) 848
Total comprehensive (expense)/income attributable to:
The owners of the parent (831) 848
Non-controlling interest (2) −
For the year ended 31 December
£’000 Notes 2018 2017
Assets
Non-current assets
Goodwill 10 50,937 51,413
Intangible assets 11 51,334 54,037
Property, plant & equipment 477 825
Deferred tax assets 8 1,699 1,603
Other financial assets 59 72
Other non-current assets 294 −
Total non-current assets 104,800 107,950
Current assets
Inventories 14,891 16,795
Trade receivables 13,084 16,680
Available-for-sale financial assets − 464
Other current assets 2,736 1,934
Cash and cash equivalents 8,035 7,579
Total current assets 38,746 43,452
Total assets 143,546 151,402
Liabilities
Current liabilities
Borrowings 12 (648) (633)
Trade payables (11,907) (14,128)
Tax payables (1,016) (1,520)
Accrued charges & deferred income 13 (2,325) (2,116)
Other current liabilities (3,864) (3,201)
Total current liabilities (19,760) (21,598)
Non-current liabilities
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY YEAR ENDED 31ST DECEMBER 2018
Borrowings 12 (30,975) (32,854)
Deferred tax liabilities 8 (5,521) (6,454)
Deferred income 13 (617) (780)
Provisions (81) (72)
Total non-current liabilities (37,194) (40,160)
Total Liabilities (56,954) (61,758)
Net Assets 86,592 89,644
Equity
Share capital 14 12,012 11,983
Share premium 132,729 132,588
Reverse acquisition reserve (56,762) (56,762)
Accumulated losses (4,732) (1,347)
Other reserves 3,345 3,180
Equity attributable to the owners of the parent 86,592 89,642
Non-controlling interest 14 − 2
Total equity 86,592 89,644
£’000
Attributable to the owners of the parents Share
capital
Share premium
Treasury shares
Accumulated losses
Reverse acquisition reserve
Other
reserve Total
Non- controlling interest
Total equity At 1 January, 2018 11,983 132,588 − (1,347) (56,762) 3,180 89,642 2 89,644
Net loss − − − (996) − − (996) (2) (998)
Other comprehensive
income − − − − − 165 165 − 165
Total comprehensive
expense − − − (996) − 165 (831) (2) (833)
Dividends paid − − − (2,401) − − (2,401) − (2,401)
Exercise of share
options 29 141 − − − − 170 − 170
Share based payments − − − 12 − − 12 − 12
At 31 December, 2018 12,012 132,729 − (4,732) (56,762) 3,345 86,592 − 86,592
£’000
Share capital
Share premium
Treasury shares
Retained earnings/Acc
umulated losses
Reverse acquisition reserve
Other
reserve Total
Non- controlling interest
Total equity
At 1 January, 2017 4,244 6,687 − 1,258 5,146 2,518 19,853 2 19,855
Net profit − − − 184 − − 184 − 184
Other comprehensive income
− − − − − 662 662 − 662
Total comprehensive income
− − − 184 − 662 846 − 846
Dividends paid − − − (2,816) − − (2,816) − (2,816)
Shares issued as consideration
5,750 94,880 − − − − 100,630 − 100,630
Exercise of share options
275 3,953 − − − − 4,228 − 4,228
Share issue cost − (1,218) − − − − (1,218) − (1,218)
Arising on reverse acquisition
− − − − (61,908) − (61,908) − (61,908)
Issue of new shares 1,714 28,286 − − − − 30,000 − 30,000
Reverse acquisition reserve
Reverse acquisition reserve represents the reserve that has been created upon the reverse acquisition of Animalcare Group plc.
Other reserve
Other reserve mainly relates to currency translation differences. These exchange differences arise on the translation of subsidiaries with a functional currency other than Sterling.
CONSOLIDATED CASH FLOW STATEMENT YEAR ENDED 31ST DECEMBER 2018 Cash consideration for
Ecuphar
− − − − − − − − −
Share based payments − − − 27 − − 27 − 27
At 31 December, 2017 11,983 132,588 − (1,347) (56,762) 3,180 89,642 2 89,644
£’000 Notes 2018 2017
Operating activities
Loss/profit before tax from continuing operations (357) 377
Loss/profit before tax from discontinued operations 3 (776) 167
Loss/Profit before tax (1,133) 544
Non-cash and operational adjustments
Depreciation of property, plant & equipment 333 327
Amortization of intangible assets 11 7,965 6,053
Impairment of intangible assets 11 852 −
Impairment of goodwill 10 456 −
Share-based payment expense 12 27
Loss/(gain) on disposal of property, plant & equipment (2) 2
Loss on disposal of subsidiary 3 682 −
Movement allowance for bad debt and inventories 620 652
Financial income (254) (91)
Financial expense 879 747
Impact of foreign currencies 16 25
Other 2 (30)
Movements in working capital
Increase in trade receivables (540) (2,079)
Increase in inventories (1,207) (1,359)
Increase /(decrease) in payables 904 (2,115)
Income tax paid (2,155) (278)
Net cash flow from operating activities 7,430 2,425
Investing activities
Purchase of property, plant & equipment (213) (184)
Purchase of intangible assets 11 (4,568) (2,379)
Proceeds from the sale of property, plant & equipment (net) 6 31
Payments to acquire subsidiaries 3 − (33,145)
Cash and cash equivalents acquired under reverse acquisition 3 − 6,293
Proceeds from sale of subsidiary 3 2,403 −
Sale/(purchase) of available for sale financial investments 459 (45)
Net cash flow used in investing activities (1,913) (29,429)
£’000 Notes
For the year ended
31 December
2018 2017
Financing activities
Proceeds from loans and borrowings and convertible debt − 8,298
1. Financial information
The financial information set out above does not constitute the Company's statutory accounts for the year ended 31st December 2018 but is derived from the 2018 accounts. The statutory accounts of Animalcare Group plc for the year ended 31st December 2017 have been delivered to the Registrar of Companies and those for 2018 will be delivered in due course.
The external auditor has reported on those accounts; the report was (i) unqualified, (ii) did not include references to any matters to which the external auditor drew attention by way of emphasis without qualifying the reports and (iii) did not contain statements under section 498(2) or (3) of the Companies Act 2006.
2. Basis of preparation
The Group financial statements have been prepared and approved by the Directors under the historical cost convention, except for the revaluation of certain financial instruments, in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union “adopted IFRSs”) and the Companies Act 2006 as applicable to companies reporting under IFRS. They have also been prepared in accordance with the requirements of the AIM Rules.
This is the first set of the Group’s annual financial statements in which IFRS 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments have been applied.
The consolidated financial statements cover the year ended 31st December 2018 and comprise the consolidated results of the Group. On 13th July 2017 the Group completed the reverse acquisition of Ecuphar NV (“Ecuphar”). In the comparatives financial statements, for the year ending 31st December 2017, the results of the group are included as of the 13th of July 2017. For the period from 1st January 2017 to the date of the reverse acquisition the results of Ecuphar, the substance of the reverse acquisition, are solely shown.
Wholesale divestment 2018
Following the divestment of the Wholesaling business Medini NV registered in Belgium, Legeweg 157i, 8020 Oostkamp on 4th September 2018, 2017 financial information have been restated in accordance with IFRS 5, to show continuing
operations separately from discontinued operations. Both continuing and discontinued operations were restated to include elements relating to transactions between entities which were previously eliminated in the consolidation as intra-group.
Reverse acquisition Animalcare Group Plc 2017
The accounting policy adopted by the Directors applies the principles of IFRS 3 (Revised) ‘Business Combinations’ in identifying the accounting parent as Ecuphar NV and the presentation of the Group consolidated statements of the Company (the legal parent) as a continuation of financial statements of the accounting parent or legal subsidiary (Ecuphar NV).
Repayment of loans and borrowings (2,257) (649)
Receipts from issue of share capital 170 29,402
Dividends paid (2,401) (2,816)
Interest paid (637) (528)
Other financial expense 11 (129)
Net cash flow (used in)/from financing activities (5,114) 33,578
Net increase of cash and cash equivalents 403 6,574
Cash and cash equivalents at beginning of year 7,579 951
Exchange rate differences on cash and cash equivalents 53 54
Cash and cash equivalents at end of year 8,035 7,579
For the year ended 31 December
£’000 Notes 2018 2017
Reconciliation of net cash flow to movement in net debt
Net increase in cash and cash equivalents in the year 403 6,574
Cash flow from decrease/(increase) in debt financing 2,257 (7,649)
Foreign exchange differences on cash and borrowings (349) (1,051)
Movement in net debt in the year 2,311 (2,126)
Net debt at the start of the year (25,908) (23,782)
Debt transferred on sale of subsidiary 3 9 −
Net debt at the end of the year (23,588) (25,908)
This policy reflects the commercial substance of this transaction as follows:
• The original shareholders of the legal subsidiary undertaking were the most significant shareholders following admission to AIM, owning 46.9% of the issued share capital;
• The assets and liabilities of the legal subsidiary Ecuphar NV are recognised and measured in the Group financial statements at the pre-combination carrying amounts without restatement to fair value;
• The retained earnings and other equity balances recognised in the Group financial statements reflect the retained earnings and other equity balances of Ecuphar NV immediately before the business combination;
• The results of the period from 1st January 2017 to the date of the business combination are those of Ecuphar NV;
• The equity structure appearing in the Group financial statements reflects the equity structure of the legal parent, including the equity instruments issued under the share for share exchange to effect the business combination and adjusted in accordance with IFRS 3. This results in the creation of a ‘reverse acquisition reserve’ as at 1st January 2017, being the difference between the Company equity structure and that of Ecuphar NV.
3. Business Combinations and disposals of subsidiaries Business combinations
Reverse acquisition of Animalcare Group plc
On 13th July 2017 Animalcare Group plc acquired 100% of the share capital of Ecuphar NV for a total consideration of
£133,775k, satisfied through a combination of a share-for-share exchange and £33,145k in cash net of commissions.
The acquisition of Ecuphar NV by Animalcare Group plc is deemed to be a reverse acquisition under the provisions of IFRS 3
“Business Combinations”.
In accounting for a reverse acquisition (rather than an acquisition) the combined financial statements are deemed to be a continuation of the books of the legal acquiree (Ecuphar NV) rather than a continuation of those of the legal acquirer (Animalcare Group plc).
The assets and liabilities of the Ecuphar NV are recognised and measured in the Group financial statements at the pre- combination carrying amounts, without restatement to fair value and no goodwill arises in relation to them.
Conversely, the assets of Animalcare Group plc and Animalcare Ltd are consolidated at their fair values.
The overall effect is that the consolidated financial statements are prepared from an Ecuphar NV perspective rather than Animalcare Group plc, and in summary this means:
̶ The comparative consolidated financial information is that of Ecuphar NV rather than that of Animalcare Group plc;
̶ The result for the year and consolidated cumulative profit and loss reserves are those of the Ecuphar NV plus the post- acquisition results of the Animalcare Group plc;
̶ A reverse acquisition reserve of £ (56,762)k has been created;
̶ The share capital and share premium account are that of Animalcare Group plc; and
̶ The cost of the combination has been determined from the perspective of Ecuphar NV.
Goodwill arises on the reverse acquisition when comparing the deemed fair value consideration of Animalcare Group plc acquiring the shares of Ecuphar NV. The fair value of the consideration is the market capitalisation of Animalcare Group plc at the acquisition date based on the closing share price on 12th July of 355p per share.
Reverse Acquisition Animalcare Group Plc
£’000
Carrying value at acquisition date
Fair value adjust- ments
Fair value at acquisi- tion date Assets
Historical goodwill 12,711 (12,711) −
Intangible assets 4,658 30,957 35,615
Tangible assets 227 − 227
Deferred tax asset 149 885 1,034
Inventory 2,014 401 2,415
Trade receivables 3,392 − 3,392
Other current assets 559 − 559
Cash 6,293 − 6,293
The acquisition consideration, net assets and goodwill are based upon the reverse acquisition of Animalcare Group plc by Ecuphar NV. The fair value of the consideration is the market capitalisation of Animalcare Group plc at the closing share price of 355p per share on 12th July 2017. Transaction costs of equity transactions relating to the issue and readmission of the Company’s shares are accounted for as a deduction from equity where they relate to the issue of new shares.
The fair value of the net assets acquired and shown in the table above was £34,290k. The fair value of the consideration was
£75,338k resulting in goodwill on reverse acquisition of £41,048k. In addition, the fair value uplift of inventory amounted to
£401k, the fair value uplift of the identified intangibles amounted to £30,957k. Deferred tax assets and liabilities respectively were increased by £885k and £(6,843)k.
Disposal of subsidiaries
On 4th September 2018, the Group announced and completed the disposal of its Wholesaling business Medini NV registered in Belgium, Legeweg 157i, 8020 Oostkamp.
The Group recognised a loss including expenses in relation to the disposal of £682k during the year ending 31st December 2018. This is based on the total consideration of £2,989k and a net asset value of £3,622k, excluding intercompany debt.
The Group has received an initial cash consideration of £2,413k including intercompany loan balances due from the
Wholesale Division to other Animalcare Group Plc companies. A further £362k is payable to on 30th June 2019 in relation to the remaining intercompany balance owed. The balance of approximately £214k is subject to achieving specific revenue targets between 1st July 2019 and 30th June 2020 and payable in July 2020.
In accordance with IFRS 5, the income statement for the twelve months ended 31 December 2017 and 2018 have been restated to show continuing operations separately from discontinued operations. Both continuing and discontinued
operations were restated to include elements relating to transactions between entities which were previously eliminated in the consolidation as intra-group. The effect of including these elements is shown as consolidation adjustments.
30,003 19,532 49,535 Liabilities
Deferred tax liabilities (414) (6,843) (7,257)
Trade payables (3,948) − (3,948)
Other liabilities (4,040) − (4,040)
(8,402) (6,843) (15,245)
Total identified assets and liabilities 21,601 12,689 34,290
Goodwill 41,048
Fair value of consideration − − 75,338
£’000
Continuing operations 2018
Discontinued operations
2018
Consolidation adjustments 2018
Total continuing and discontinued operations 2018
Revenue 72,470 16,572 (719) 88,323
Cost of sales (35,131) (15,059) 689 (49,501)
Gross profit 37,339 1,513 (30) 38,822
Research and development expenses (4,762) − − (4,762)
Selling and marketing expenses (12,435) (1,111) 46 (13,500)
General and administrative expenses (16,666) (387) (18) (17,071)
Net other operating expenses (3,259) (762) 2 (4,019)
Operating profit/(loss) 217 (746) − (529)
Financial expenses (840) (39) 20 (859)
Financial income 266 9 (20) 255
Loss before tax (357) (776) − (1,133)
Income tax 135 − − 135
Net loss (222) (776) − (998)
£’000
Continuing operations 2017
Discontinue operations 2017
Consolidation adjustments 2017
As reported
last year 2017
Revenue 62,291 23,938 (2,553) 83,676
Cost of sales (30,367) (21,523) 2,477 (49,413)
The net cash flow by discontinued operations can be found below:
The major classes of assets and liabilities of the Wholesaling business at the disposal date can be found below:
Gross profit 31,924 2,415 (76) 34,263
Research and development expenses (2,799) − − (2,799)
Selling and marketing expenses (12,592) (1,594) 88 (14,098)
General and administrative expenses (13,805) (625) 26 (14,404)
Net other operating expenses (1,713) (12) (38) (1,762)
Operating profit 1,016 184 − 1,200
Financial expenses (735) (30) 18 (747)
Financial income 96 13 (18) 91
Profit before tax 377 167 − 544
Income tax (292) (68) − (360)
Net profit 85 99 − 184
£’000
For the year ended 31 December
2018 2017
Net cash flow from operating activities 133 107
Net cash flow used in investing activities (94) (83)
Net cash flow used in financing activities (28) (30)
Net increase/(decrease) of cash & cash equivalents 11 (6)
£’000
Non-current assets
Goodwill 106
Intangible assets 2
Property, plant & equipment 244
Current assets
Inventories 2,669
Trade receivables 2,451
Other current assets 77
Cash and cash equivalents 10
Total assets classified as held for sale 5,559
Current liabilities
Borrowings (9)
Trade payables (1,690)
Tax payables (52)
Accrued charges & deferred income (12)
Other current liabilities (169)
Non-current liabilities
Deferred tax liabilities (5)
Liabilities associated with assets classified as held for sale (1,937)
Total net assets 3,622
Consideration received or receivable:
Cash 2,413
Receivable 576
Total disposal consideration 2,989
Carrying amount of net assets sold (3,622)
Loss on sale before reclassification of foreign currency translation reserve (633)
Reclassification of foreign currency translation reserve (49)
Loss on sale (682)
Loss attributable to minority (2)
Loss attributable to owners of the parent (680)
Selling price received in cash 2,413
Cash and cash equivalents transferred (10)
Total cash flow 2,403
4. Non-Underlying items
The amortisation charge of acquisition-related intangibles largely relates to the Esteve acquisition of £2,037k (2017:
£2,017k) and the reverse acquisition of Animalcare Group plc of £3,676k (2017: £1,685k, which was the amortization impact from the acquisition date, 12th of July 2017, until the 31st of December 2017).
Restructuring costs of £1,235 k include £203k in relation to compensation for loss of office in respect of Iain Menneer and a further £382k for other senior management.
5. Segment information – from continuing operations
For management purposes, the Group was organised into 2 segments: the Pharmaceuticals and the Wholesale segments.
From 2018 onwards, the Group will only report one segment, being Pharmaceuticals, due to the sale of its Wholesaling business.
The Pharmaceutical segment is active in the development and marketing of innovative pharmaceutical products that provide significant benefits to animal health.
The Wholesale segment focused on the sale of veterinary pharmaceuticals, supplies and instruments in the Belgian market and is presented under discontinued operations in the financial information.
The measurement principles used by the Group in preparing this segment reporting are also the basis for segment performance assessment. The Board of Directors of the Group acts as the Chief Operating Decision Maker. As a
performance indicator, the Chief Operating Decision Maker controls performance by the Group’s revenue, gross margin, Underlying EBITDA and EBITDA. EBITDA is defined by the Group as net profit plus finance expenses, less financial income, plus income taxes and deferred taxes, plus depreciation, amortisation and impairment. Underlying EBITDA equals EBITDA plus non-underlying items.
The following table summarises the segment reporting from continuing operations for each of the reportable periods. As management’s controlling instrument is mainly revenue-based, the reporting information does not include assets and liabilities by segment and is as such not presented per segment.
£’000
For the year ended 31 December
2018 2017
Amortisation and impairment of acquisition related intangibles
Classified within Research and development expenses 1,296 751
Classified within General and administrative expenses 4,789 3,591
Classified within net other operating expenses 513 -
Total amortisation and impairment of acquisition related intangibles 6,598 4,342
Fair value uplift of inventory acquired through reverse acquisition - 401
Restructuring costs 1,235 -
Acquisition and integration costs 485 1,454
Impairment on goodwill and intangibles 796 -
Other non-underlying items 273 347
Total non-underlying items before taxes 9,387 6,544
Tax impact (2,151) (1,454)
Total non-underlying items after taxes from continuing operations 7,236 5,090
Other non-underlying items from discontinued operations 134 10
Loss on disposal 682 -
Total non-underlying items after taxes 8,052 5,100
£’000 Pharma Wholesale
Total segments
Adjustments and
eliminations Consolidated For the year ended 31 December 2018
Revenues 72,470 − 72,470 − 72,470
Gross Margin 37,339 − 37,339 − 37,339
Gross Margin % 52% 52% 52%
Segment underlying EBITDA 11,798 − 11,798 − 11,798
Segment underlying EBITDA % 16% 16% 16%
Segment EBITDA 9,805 − 9,805 − 9,805
Segment EBITDA % 14% 14% 14%
The segment EBITDA is reconciled with the consolidated net profit of the year as follows:
Non-current assets excluding deferred tax assets and financial instruments located in Belgium, Spain, Portugal, the United Kingdom and other geographies are as follows:
Revenue by product category
Revenue by geographical area:
For the year ended 31 December 2017
Revenues 62,291 − 62,291 − 62,291
Gross Margin 31,924 − 31,924 − 31,924
Gross Margin % 51% 51% 51%
Segment underlying EBITDA 9,698 − 9,698 − 9,698
Segment underlying EBITDA % 16% 16% 16%
Segment EBITDA 7,496 − 7,496 − 7,496
Segment EBITDA % 12% 12% 12%
£’000
For the year ended 31 December
2018 2017
Segment EBITDA 9,805 7,496
Depreciation, amortization and impairment (9,588) (6,480)
Operating profit 217 1,016
Financial expenses (840) (735)
Financial income 266 96
Income taxes (869) (592)
Deferred taxes 1,004 300
Net (loss)/profit (222) 85
£’000
For the year ended 31 December
2018 2017
Belgium 18,423 19,691
Spain 2,127 2,170
Portugal 4,122 4,101
UK 73,913 76,010
Other 4,510 4,375
Non-current assets excluding deferred tax assets and financial instruments 103,101 106,347
£’000
For the year ended 31 December
2018 2017
Companion animals 44,465 33,670
Production animals 22,824 23,680
Horses 4,618 4,682
Petfood, Instrumentation and Services 563 259
Total 72,470 62,291
£’000
For the year ended 31 December
2018 2017
Europe 71,507 61,424
Belgium 8,260 8,781
The Netherlands 1,719 1,142
United Kingdom 16,802 9,459
Germany 9,784 8,907
Revenue by category:
Product revenue is recognised when the performance obligation is satisfied at a point in time. Service revenue is recognised by reference of the stage of completion.
Share Options:
During the year Iain Menneer exercised 5,142 share options granted in 2014 under the Save As You Earn scheme (SAYE) at an option price of £1.05 per share. The value of this exercise was £5,399. The SAYE options held by Chris Brewster, totalling options over 8,571 shares, lapsed during the year. As at 31st December 2018, no options are held or have been granted to the Directors.
6 Financial expenses – from continuing operations Financial expenses includes the following elements:
7 Financial income – from continuing operations Financial income includes the following elements:
8 Income tax – from continuing operations Income tax
The following table shows the breakdown of the tax expense for 2018 and 2017:
Spain 20,706 20,909
Italy 4,984 4,458
Portugal 4,600 4,514
European Union – other 4,652 3,254
Asia 558 471
Middle East Africa 139 45
Other 266 351
Total 72,470 62,291
£’000
For the year ended 31 December
2018 2017
Product sales 71,025 62,162
Services sales 1,445 129
Total 72,470 62,291
£’000
For the year ended 31 December
2018 2017
Interest expense 637 527
Foreign currency losses 119 111
Other financial expenses 84 97
Total 840 735
£’000
For the year ended 31 December
2018 2017
Foreign currency exchange gains 192 64
Other financial income 74 32
Total 266 96
£’000
For the year ended 31 December
2018 2017
Current tax charge (963) (770)
Tax adjustments in respect of previous years 94 178
Total current tax charge (869) (592)
